No | Age | Sex | Surgery type | Tumor location | Tumor morphology | Tumor size (pathology, cm) | Tumor depth (pathology) | LNM | Resection margin | BRAF | PD-L1 (TPS) | Adjuvant therapy | Disease-free survival (months) | Recurrent organ | Overall survival (months) | Outcome |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 48 | M | 3-field | Upper | DI | 0.8 | SM | 0/13 | Negative | Not detected | N/A | No | 36 | Anastomosis | 59 | Dead |
2 | 53 | F | I-L | Middle | MF | 7.5 | SM | 0/33 | Negative | Not detected | N/A | No | 15 | Femur, lung | 38 | Dead |
3 | 70 | M | I-L | Lower | MF | 8.5 | PM | 2/46 | Negative | N/A | 30% | Pembrolizumab | 4 | Peritoneum | 25 | Alive |
4 | 41 | F | I-L | Lower | MF | 2.2 | SM | 3/21 | Negative | N/A | N/A | N/A | N/A | N/A | 22 | Alive |
5 | 65 | M | TG | EGJ | MF | 4.0 | SM | 9/40 | Negative | N/A | N/A | IFN-α | 4 | Anastomosis, liver | 11 | Dead |
6 | 51 | M | I-L | Lower | MF | 6.0 | PM | 4/17 | Negative | Not detected | 1% | Pembrolizumab | 3 | LN, peritoneum, abdominal wall | 9 | Dead |
7 | 77 | M | I-L | Lower | MF | 9.0 | PM | 9/25 | Negative | N/A | N/A | No | 5 | Anastomosis, liver, peritoneum | 8 | Dead |
8 | 69 | M | I-L | Lower | MF | 3.5 | SM | 0/7 | Negative | Not detected | N/A | IFN-α | 4 | Neo-esophagus | 7 | Dead |
9 | 57 | M | 3-field | Middle | MF | 4.5 | SM | 5/80 | Negative | Not detected | N/A | RT followed by IFN-α | 1 | Supraclavicular LN | 6 | Dead |
10 | 53 | M | I-L | Lower | MF | 3.5 | SM | 0/36 | Negative | N/A | N/A | No | 4 | Brain | 6 | Dead |